Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.57 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.57 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.57 |
| ▸ | GLS | O94925 | 3/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352872 | 0.84 | L3MBTL1 (0.60) | L3MBTL1CACNA1GCACNA1HCACNA1IGLS | |
| SCHEMBL14975386 | 0.83 | GLS (0.65) | CACNA1GCACNA1HCACNA1IGLSKMT2A | |
| SCHEMBL14975080 | 0.78 | GLS (0.60) | GLS | |
| SCHEMBL29351282 | 0.78 | GLS (0.60) | GLS | |
| SCHEMBL31240719 | 0.78 | MAPK10 (0.66) | L3MBTL1CACNA1GCACNA1HCACNA1IMAPK8 | |
| SCHEMBL18861419 | 0.77 | GLS (0.58) | L3MBTL1CACNA1GCACNA1HCACNA1IGLS | |
| SCHEMBL18357648 | 0.76 | RAB9A (0.48) | GLSALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL18135199 | 0.75 | MEN1 (0.61) | L3MBTL1CACNA1GCACNA1HCACNA1IPSEN1 | |
| SCHEMBL1947883 | 0.75 | ALDH1A1 (0.61) | L3MBTL1CACNA1GCACNA1HCACNA1IGLS | |
| SCHEMBL3431712 | 0.75 | L3MBTL1 (0.61) | L3MBTL1CACNA1GCACNA1HCACNA1IGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783533-B2 | Glutaminase inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-10 | — | — | US | disclosed |
| US-20160318921-A1 | NOVEL GLUTAMINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318921-A1 | NOVEL GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | L3MBTL1 3297/4885CACNA1G 3958/4885CACNA1H 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.